# SGMT (Sagimet Biosciences Inc.) - SEC EDGAR Financial Statements

> Sagimet Biosciences Inc. reported $282.1M in total assets and a net loss of $53.32M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/SGMT
- Markdown: https://convexityos.com/fundamentals/SGMT.md
- SEC CIK: 0001400118
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:39 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001400118&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$59.86M | Operating profit |
| Net Income | FY 2025 | -$53.32M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.86 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $236.4M | Total debt: $2.02M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | $2.00M | -- |
| Research & Development | $39.05M | $38.44M | $19.78M | $24.92M |
| Total Operating Expenses | $56.89M | $54.45M | $32.74M | $31.05M |
| **Operating Income** | -$56.89M | -$54.45M | -$30.74M | -$31.05M |
| Income Tax Expense | $0 | $0 | -- | -- |
| **Net Income** | -$51.04M | -$45.57M | -$27.88M | -$30.50M |
| Basic EPS | -$1.58 | -$1.45 | -$2.66 | -$165.20 |
| **Diluted EPS** | -$1.58 | -$1.45 | -$2.66 | -$165.20 |
| Basic Shares Outstanding | 32.3M | 31.4M | 10.5M | 184.6K |
| Diluted Shares Outstanding | 32.3M | 31.4M | 10.5M | 184.6K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $16.34M | $11.54M | $7.00M | $6.73M | $9.73M | $7.25M | $15.34M | $14.22M |
| Total Operating Expenses | $21.57M | $15.82M | $11.71M | $10.77M | $14.33M | $11.93M | $19.86M | $18.20M |
| **Operating Income** | -$21.57M | -$15.82M | -$11.71M | -$10.77M | -$14.33M | -$11.93M | -$19.86M | -$18.20M |
| **Net Income** | -$19.15M | -$13.95M | -$10.65M | -$9.57M | -$12.91M | -$10.39M | -$18.18M | -$16.20M |
| Basic EPS | -$0.31 | -$0.26 | -$0.33 | -- | -$0.40 | -$0.32 | -$0.56 | -- |
| **Diluted EPS** | -$0.31 | -$0.26 | -$0.33 | -- | -$0.40 | -$0.32 | -$0.56 | -- |
| Basic Shares Outstanding | 62.3M | 53.1M | 32.6M | -- | 32.5M | 32.2M | 32.2M | -- |
| Diluted Shares Outstanding | 62.3M | 53.1M | 32.6M | -- | 32.5M | 32.2M | 32.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $35.02M | $75.84M | $75.14M | $158K |
| Short-Term Investments | $78.10M | $75.41M | $19.76M | $32.19M |
| **Cash & Short-Term Investments** | $113.1M | $158.7M | $94.90M | $32.34M |
| Other Current Assets | $199K | $157K | $74K | $34K |
| **Total Current Assets** | $116.4M | $152.8M | $96.65M | $32.79M |
| Long-Term Investments | $0 | $7.41M | -- | -- |
| Other Non-Current Assets | $0 | -- | -- | -- |
| **Total Non-Current Assets** | $78K | $7.49M | $73K | $239K |
| **Total Assets** | $116.5M | $160.3M | $96.72M | $33.03M |
| Accounts Payable | $1.31M | $1.43M | $186K | $1.12M |
| Other Current Liabilities | $27K | $5.0K | $233K | $57K |
| **Total Current Liabilities** | $5.10M | $4.45M | $5.65M | $5.28M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $82K |
| **Total Liabilities** | $5.10M | $4.45M | $5.65M | $5.36M |
| **Total Debt (incl. Leases)** | $78K | $78K | $65K | $211K |
| Common Stock | -- | -- | -- | $1.0K |
| Retained Earnings | -$346.3M | -$295.3M | -$249.7M | -$221.9M |
| Accumulated Other Comp. Income | $120K | $230K | $30K | -$84K |
| **Total Stockholders' Equity** | $111.4M | $155.8M | $91.06M | -$186.9M |
| Total Equity | $111.4M | $155.8M | $91.06M | -$186.9M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $111.0M | $165.9M | $36.63M | $35.02M | $32.50M | $42.33M | $64.72M | $75.84M |
| Short-Term Investments | $125.4M | $74.23M | $67.91M | $78.10M | $84.20M | $83.08M | $79.85M | $75.41M |
| **Cash & Short-Term Investments** | $275.8M | $257.6M | $104.5M | $113.1M | $125.5M | $135.5M | $144.6M | $158.7M |
| Other Current Assets | $302K | $226K | $248K | $199K | $253K | $173K | $263K | $157K |
| **Total Current Assets** | $240.7M | $244.0M | $107.7M | $116.4M | $119.5M | $127.2M | $146.1M | $152.8M |
| Long-Term Investments | $39.42M | $17.44M | -- | $0 | $8.81M | $10.06M | -- | $7.41M |
| Other Non-Current Assets | $55K | $55K | -- | $0 | -- | -- | $62K | -- |
| **Total Non-Current Assets** | $41.37M | $19.44M | $39K | $78K | $8.92M | $10.21M | $100K | $7.49M |
| **Total Assets** | $282.1M | $263.4M | $107.8M | $116.5M | $128.4M | $137.4M | $146.2M | $160.3M |
| Accounts Payable | $1.81M | $1.13M | $2.30M | $1.31M | $4.24M | $1.92M | $3.22M | $1.43M |
| Other Current Liabilities | $13K | $26K | $15K | $27K | $8.0K | $1.0K | $16K | $5.0K |
| **Total Current Liabilities** | $37.98M | $5.42M | $5.30M | $5.10M | $9.15M | $7.25M | -- | $4.45M |
| **Total Non-Current Liabilities** | $1.93M | $1.86M | $0 | $0 | $0 | $0 | -- | $0 |
| **Total Liabilities** | $39.91M | $7.28M | $5.30M | $5.10M | $9.15M | $7.25M | $7.18M | $4.45M |
| **Total Debt (incl. Leases)** | $2.02M | $1.94M | $39K | $78K | $115K | $152K | $39K | $78K |
| Retained Earnings | -$390.1M | -$371.0M | -$357.0M | -$346.3M | -$336.8M | -$323.9M | -$313.5M | -$295.3M |
| Accumulated Other Comp. Income | -$560K | -$77K | $8.0K | $120K | $117K | $76K | $121K | $230K |
| **Total Stockholders' Equity** | $242.2M | $256.2M | $102.5M | $111.4M | $119.3M | $130.2M | $139.0M | $155.8M |
| Total Equity | $242.2M | $256.2M | $102.5M | $111.4M | $119.3M | $130.2M | $139.0M | $155.8M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$51.04M | -$45.57M | -$27.88M | -$30.50M |
| Stock-Based Compensation | $6.45M | $5.29M | $4.99M | $1.88M |
| **Operating Cash Flow** | -$45.65M | -$42.44M | -$23.77M | -$24.49M |
| Purchases of Investments | -$106.9M | -$108.1M | -$19.62M | -$41.45M |
| **Investing Cash Flow** | $4.56M | -$61.68M | $12.58M | -$32.01M |
| Common Stock Issued | $0 | $105.8M | -- | -- |
| **Financing Cash Flow** | $275K | $104.8M | $86.17M | -$73K |
| **Net Change in Cash** | $1.60M | -$11.12M | $1.88M | $101.7M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$19.15M | -$13.95M | -$10.65M | -$9.57M | -$12.91M | -$10.39M | -$18.18M | -$16.20M |
| Stock-Based Compensation | $2.39M | $3.69M | $1.84M | $1.69M | $1.69M | $1.60M | $1.47M | $1.53M |
| **Operating Cash Flow** | -$12.11M | -$11.10M | -$8.61M | -$11.83M | -$10.18M | -$9.10M | -$14.54M | -$11.02M |
| Purchases of Investments | -$98.72M | -$39.90M | -$6.75M | -$17.08M | -$31.26M | -$42.95M | -$15.57M | -- |
| **Investing Cash Flow** | -$73.25M | -$24.02M | $10.22M | $14.36M | $75K | -$13.29M | $3.41M | $9.85M |
| Common Stock Issued | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Financing Cash Flow** | -- | -- | -- | -- | -- | -- | -- | $0 |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -1537.0% | -- |
| **Net Profit Margin** | -- | -- | -1393.8% | -- |
| Return on Equity (ROE) | -45.8% | -29.2% | -30.6% | -- |
| Return on Assets (ROA) | -43.8% | -28.4% | -28.8% | -92.3% |
| Current Ratio | 22.82x | 34.30x | 17.09x | 6.21x |
| Quick Ratio | 22.17x | 35.63x | 16.78x | 6.13x |
| Debt to Equity | 0.00x | 0.00x | 0.00x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -22.0% | -18.4% | -42.5% | -45.8% | -48.4% | -45.6% | -41.1% | -29.2% |
| Return on Assets (ROA) | -18.9% | -17.9% | -40.4% | -43.8% | -44.9% | -43.2% | -39.1% | -28.4% |
| Current Ratio | 6.34x | 45.02x | 20.34x | 22.82x | 13.06x | 17.55x | -- | 34.30x |
| Quick Ratio | 7.26x | 47.54x | 19.73x | 22.17x | 13.72x | 18.70x | -- | 35.63x |
| Debt to Equity | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
